[en] During the past 2 decades, many interventions were proven effective in the management of postmenopausal osteoporosis. The objective of an anti-osteoporosis treatment is to reduce fracture rates, ideally at all skeletal sites (i.e. spine, hip, and other non-spine). The armamentarium against osteoporosis includes anti-resorptive agents (i.e. bisphosphonates, selective estrogen receptor modulators and denosumab), bone-forming agents (i.e. peptides from the parathyroid hormone family) and one agent with a dual mechanism of action (i.e. strontium ranelate). All these medications combine anti-fracture efficacy with a reasonable benefit/risk profile. However, the choice of a particular chemical entity, in one individual patient is based on the knowledge and expertise of the physician. Prioritization of drugs should be based on the individual profile of the patient, the severity of osteoporosis and the specific contraindications, warnings and precautions of use of the various available medications.
Disciplines :
General & internal medicine
Author, co-author :
Reginster, Jean-Yves ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
NEUPREZ, Audrey ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur
Dardenne, Nadia ; Université de Liège - ULiège > Département des sciences de la santé publique > Informatique médicale et biostatistique
Beaudart, Charlotte ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé
Language :
English
Title :
Efficacy and safety of currently marketed anti-osteoporosis medications
Publication date :
2014
Journal title :
Best Practice and Research. Clinical Endocrinology and Metabolism
Harvey N, Dennison E, Cooper C. Osteoporosis: Impact on health and economics. Nat Rev Rheumatol 2010; 6: 99-1051.
Kaufman JM, Reginster JY, Boonen S, et al. Treatment of osteoporosis in men. Bone 2013; 53: 34-44.
Kanis JA, McCloskey EV, Johansson H, et al. Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) . European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2013; 24: 23-57.
Gallacher SJ, Dixon T. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate and denosumab) on bone quality: A systematic review. Calcif Tissue Int 2010; 87: 469-84.
Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2011; 71: 65-78.
Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: A consensus document by the Belgian Bone Club. Osteoporos Int 2010; 21: 1657-80.
Boonen S, Body JJ, Boutsen Y, et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: A consensus document of the Belgian Bone Club. Osteoporos Int 2005; 16: 239-54.
Riggs BL, Hartmann LC. Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 2003; 348: 618-29.
Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: A randomized trial. J Bone Miner Res 1998; 13: 1747-54.
Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Med Am Assoc 1999; 282: 637-45.
Maricic M, Adachi JD, Sarkar S, et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postmenopausal women with osteopororis. Arch Intern Med 2002; 162: 1140-3.
Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: Results from the MORE trial. Bone 2003; 33: 522-32.
Siris E, Adachi JD, Lu Y, et al. Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: Results from the MORE study. Osteoporos Int 2002; 13: 907-13.
Kanis JA, Johnell O, Black DM, et al. Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: A reanalysis of the Multiple Outcomes of Raloxifene Evaluation Trial. Bone 2003; 33: 293-300.
Delmas PD, Ensrud KE, Adachi JD, et al., for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: Four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-17.
Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. J Med Am Assoc 1999; 281: 2189-97.
Barrett-Connor E, Grady D, Sashegyi A, et al. MORE Investigators (Multiple Outcomes of Raloxifene Evaluation) . Raloxifene and cardiovascular events in osteoporotic postmenopausal women: Four-year results from the MORE randomized trial. J Med Am Assoc 2002; 287: 847-57.
Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751-61.
Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: Results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005; 20: 1514-24.
Neele SJ, Evertz R, De Valk-De RG, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002; 30: 599-603.
Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006; 355: 125-37.
Vogel VG, Costantino JP, Wickerman DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. J Med Am Assoc 2006; 295: 2727-41.
Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int 2012; 23: 797-809.
Christiansen C, Chesnut CH, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo-and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord 2010; 11: 130-41.
Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: Effects on the endometrium, ovaries and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009; 16: 1109-15.
Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23: 1923-34.
Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures inpostmenopausal women at high risk assessed with FRAX. Bone 2009; 44: 1049-54.
Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the efficacy of raloxifene on all clinical and vertebral fractures and its dependency on FRAX. Bone 2010; 47: 729-35.
Kaufman JM, Palacios S, Silverman S, et al. The effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX. Osteoporos Int 2013; 24: 2561-9.
Silverman SL, Chines AA, Kendler DL, et al. Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled study. Osteoporos Int 2012; 23: 351-63.
Palacios S, de Villiers TJ, Nardone Fde C, et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: Results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas 2013; 76: 81-7.
Kawate H, Takayanagi R. Efficacy and safety of bazedoxifene for postmenopausal osteoporosis. J Clin Interv Aging 2011; 6: 151-60.
Harvey JA, Holm MK, Ranganat R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009; 16: 1193-6.
de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: Results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567-76.
Mirkin S, Komm BS, Pan K, et al. Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women. Climateric 2013; 16: 338-46.
Reginster JY, Ferrari S, Peyman H. Current challenges in the treatment of osteoporosis: An opportunity for bazedoxifene. Curr Med Res Opin 2014; 30: 1165-76.
Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-43.
Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-41.
Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention trial. J Med Am Assoc 1998; 280: 2077-82.
Karpf DB, Shapiro DR, Seeman E, et al. Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. J Med Am Assoc 1997; 277: 1159-64.
Cranney A, Wells G, Willan A, et al. Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 2002; 23: 508-16.
Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189-99.
Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX) : A randomized trial. J Med Am Assoc 2006; 296: 2927-38.
De Groen PC, Lubbe DF, Hirsch IJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21.
Schnitzer T, Bone HG, Crepaldi G, et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group. Aging Milano 2000; 12: 1-12.
Dansereau RJ, Crail DJ, Perkins AC. In vitro disintegration studies of weekly generic alendronate sodium tablets (70 mg) available in the US. Curr Med Res Opin 2009; 25: 449-52.
Ringe JD, Moller G. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 2009; 30: 213-21.
Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. J Med Am Assoc 1999; 282: 1344-52.
Reginster JY, Minne HW, Hooper M, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91.
Sorensen OH, Crawford GM, Mulder H, et al. Long-term efficacy of risedronate: A 5-year placebo-controlled clinical experience. Bone 2003; 32: 120-6.
Boonen S, McClung MR, Eastell R, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 2004; 52: 1832-9.
Brown JP, Kendler DL, McClung MR, et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002; 71: 103-11.
Chesnut IC, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-9.
Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2-year results from the MOBILE study. Ann Rheum Dis 2006; 65: 6654-61.
Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long-term extension. Clin Rheumatol 2008; 27: 955-60.
Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-46.
Cranney A, Wells GA, Yetisi E, et al. Ibandronate for the prevention of nonvertebral fractures: A pooled analysis of individual patient data. Osteoporos Int 2009; 20: 291-7.
Sebba AI, Emkey RD, Kohles JD, et al. Ibandronate dose response is associated with increase in bone mineral density and reductions in clinical fractures: Results of a meta-analysis. Bone 2009; 44: 423-7.
Harris ST, Reginster JY, Harley C, et al. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: The eValuation of Ibandronate Efficacy (VIBE) database fracture study. Bone 2009; 44: 758-65.
Miller PD, Recker RR, Harris S, et al. Long-term fracture rates seen with continued ibandronate treatment: Pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 2014; 25: 349-57.
Boonen S, Haentjens P, Vandenput L, et al. Preventing osteoporotic fractures with antiresorptive therapy: Implications of microarchitectural changes. J Intern Med 2004; 255: 1-12.
Miller PD, Epstein S, Sedarati F, et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: Results from the head-to-head MOTION study. Curr Med Res Opin 2008; 24: 207-13.
Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-22.
Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-809.
Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010; 25: 91-7.
Recker RR, Lewiecki EM, Miller PD, et al. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med 2009; 122: S22-32.
Loke YK, Jeevanantham V, Singh S. Bisphosphonates and atrial fibrillation: Systematic review and meta-analysis. Drug Saf 2009; 32: 21-228.
Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008; 74: 641-8.
Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT) . J Bone Miner Res 2012; 27. 243-254.
Reid IR, Black DM, Eastell R, et al. Reduction in the risk of clinical fractures after a single dose of zoledronic acid 5 milligrams. J Clin Endocrinol Metab 2013; 98: 557-63.
Rabenda V, Vanoverloop J, Fabri V, et al. Low incidence of anti-osteoporosis treatment after hip fracture. J Bone Jt Surg 2008; 90: 2142-8.
Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006; 12: 522-8.
Tadrous M, Wong L, Mandani MM, et al. Comparative gastronintetinal safety of bisphosphonates in primary osteoporosis: A network meta-analysis. Osteoporos Int 2014; 25: 1225-35.
Shane E, Burr D, Abrahamsen B, et al. Atypical subtraochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29: 1-23.
Ettinger B, Burr DB, Ritchie RO. Proposed pathogenesis for atypical femoral fractures: Lessons from material research. Bone 2013; 55: 495-500.
Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358: 1304-6.
Rizzoli R, Akesson K, Bouxsein M, et al. Subtrochanteric fractures after long-term treatment with bisphosphonates: A European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report. Osteoporos Int 2011; 22: 373-90.
Thompson RN, Phillips JR, McCauley SH, et al. Atypical femoral fractures and bisphosphonate treatment: Experience in two large United Kingdom teaching hospitals. J Bone Joint Surg Br 2012; 94: 385-90.
Gomberg SJ, Wustrack RL, Napoli N, et al. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab 2011; 96: 1627-32.
Carvalho NN, Voss LA, Almeida MO, et al. Atypical femoral fractures during prolonged use of bisphosphonates: Shortterm responses to strontium ranelate and teriparatide. J Clin Endocrinol Metab 2011; 96: 2675-80.
Negri AL, Spivacow FR. Healing of subtrochanteric atypical fractures after strontium ranelate treatment. Clin Cases Miner Bone Metabol 2012; 9: 166-9.
Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: So many hypotheses, so few data. J Oral Maxillofac Surg 2009; 67: 61-70.
Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: A long-term complication of bisphosphonate treatment. Lancet 2006; 7: 508-14.
Lesclous P, Abi NS, Carrel JP, et al. Bisphosphonate-associated osteonecrosis of the jaw: A key role of inflammation? Bone 2009; 45: 843-52.
Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 2008; 42: 841-7.
Sb Woo, Hellstein JW, Kalmar JR. Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144: 753-61.
Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-91.
Dunstan CR, Felsenberg D, Seibel MJ. Therapy insight: The risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat Clin Pract Oncol 2007; 4: 42-55.
Cooper C, Steinbuch M, Stevenson R, et al. The epidemiology of osteonecrosis: Findings from the GPRD and THIN databases in the UK. Osteoporos Int 2010; 24: 569-77.
Khan A. Osteonecrosis of the jaw and bisphosphonates. Br Med J 2010; 340: C246.
Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial. J Am Dent Assoc 2008; 139: 32-40.
Rizzoli R, Reginster JY, Boonen S, et al. Adverse reactions and drug-drug interactions in the management of women with postmenopauxal osteoporosis. Calcif Tissue Int 2011; 89: 91-104.
Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular disease. J Am Med Assoc 2004; 292: 490-5.
Abdallah BM, Stilgren LS, Nissen N, et al. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcif Tissue Int 2005; 76: 90-7.
Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: A randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 14: 1-34.
Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2010; 361: 756-65.
Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension. J Bone Miner Res 2012; 27: 694-701.
Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 2013; 98: 4483-92.
Brown JP, Roux C, Törring O, et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res 2013; 28: 746-52.
Eastell R, Christiansen C, Grauer A, et al. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. J Bone Miner Res 2011; 26: 530-7.
McCloskey EV, Johansson H, Oden A, et al. Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 2012; 27: 1480-6.
Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res 2010; 25: 72-81.
Roux C, Hofbauer LC, Ho PR, et al. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: Efficacy and safety results from a randomized open-label study. Bone 2014; 58: 48-54.
Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: The DATA study randomized trial. Lancet 2013; 382: 50-6.
Sivolella S, Lumachi F, Stellini E, et al. Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease. Anti-Cancer Res 2013; 33: 1793-7.
Otto S, Bauman S, Ehrenfeld M, et al. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. J Craniomaxillofac Surg 2013; 41: 694-8.
Neuprez A, Coste S, Rompen E, et al. Osteonecrosis of the jaw in a male osteoporotic patient treated with denosumab. Osteoporos Int 2014; 25: 393-5.
Drampalos E, Skarpas G, Barbounakis N, et al. Atypical femoral fractures bilaterally in patient receiving denosumab. Acta Orthop 2014; 85: 3-5.
Paparodis R, Buehring B, Pelley EM, et al. A case of an unusual subtrochanteric fracture in a patient receiving denosumab. Endocr Pract 2013; 19: 64-8.
EMA. Protelos: EPAR - scientific discussion. European Medicines Agency; 2005.
Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int 2011; 22: 1659-67.
Meunier PJ, Slosman DO, Delmas PD, et al. Strontium ranelate: Dose-dependent effects in established postmenopausal vertebral osteoporosis - A 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 2002; 87: 2060-6.
Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004; 350: 459-68.
Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005; 90: 2816-22.
Meunier PJ, Roux C, Ortolani S, et al. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int 2009; 20: 1663-73.
Reginster JY, Malaise O, Neuprez A, et al. Strontium ranelate in the prevention of osteoporotic fractures. Int J Clin Pract 2007; 61: 324-8.
Reginster JY, Bruyere O, Sawicki A, et al. Long-term treatment of postmenopausal osteoporosis with strontium ranelate: Results at 8 years. Bone 2009; 45: 1059-64.
Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int 2012; 23: 1115-22.
Roux C, Reginster JY, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res 2006; 21: 536-42.
Roux C, Fechtenbaum J, Kolta S, et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2008; 67: 1736-8.
Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 2006; 21: 1113-20.
Bruyére O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab 2007; 92: 3076-81.
Bruyére O, Roux C, Badurski J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin 2007; 23: 3041-5.
EMEA. Question and answers on the safety of Protelos/Osseor (strontium ranelate) . 2007.
Reginster JY, Pelousse F, Bruyére O. Safety concerns with the long-term management of osteoporosis. Expert Opin Drug Saf 2013; 12: 507-22.
Cooper C, Reginster JY, Cortet B, et al. Long-term treatment of osteoporosis in postmenopausal women: A review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF) . Curr Med Res Opin 2012; 28: 475-91.
Grosso A, Douglas I, Hingorani A, et al. Post-marketing assessment of the safety of strontium ranelate; a novel caseonly approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008; 66: 689-94.
Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: A retrospective cohort study in the UK General Practice Research Database. Osteoporos Int 2010; 21: 1181-7.
Cacoub P, Descamps V, Meyer O, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporos Int 2013; 24: 1751-7.
Musette P, Brandi ML, Cacoub P, et al. Treatment of osteoporosis: Recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010; 21: 723-32.
Tas S, Simonart T. Management of drug rash with eosinophilia and systemic symptoms (DRESS syndrome) : An update. Dermatology 2003; 206: 353-6.
Donneau AF, Reginster JY. Cardiovascular safety of strontium ranelate: Real-life assessment in clinical practice. Osteoporos Int 2014; 25: 397-8.
Cooper C, Fox KM, Borer JS. Ischaemic cardiac events and use of strontium ranelate in postmonopausal osteoporosis: A nested case-control study in the CPRD. Osteoporos Int 2014; 25: 737-45.
Abrahamsen B, Grove EL, Vestergaard P. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate. Osteoporos Int 2014; 25: 757-62.
Svanström H, Pasternk B, Hviid A. Une of strontium ranelate and risk of acute coronary syndrome: Cohort study. Ann Rheum Dis 2014; 73: 1037-43.
Reginster JY, Neuprez A, Beaudart C, et al. Bone forming agents for the management of osteoporosis. Panminerva Med 2014; 56: 97-114.
European Medicines Agency. European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions. 21 Feb 2014. EMA/84749/2014.
Reginster JY, Taquet AN, Fraikin G, et al. Parathyroid hormone in the treatment of involutional osteoporosis: Back to the future. Osteoporos Int 1997; 7: S163-7.
Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-41.
Marcus R, Wang O, Satterwhite J, et al. The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J Bone Miner Res 2003; 18: 18-23.
Lindsay R, Scheels WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide (recombinant human parathyroid hormone (1-34) ) in postmenopausal women with osteoporosis. Arch Intern Med 2004; 164: 2024-30.
Prince R, Sipos A, Hossain A, et al. Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 2005; 20: 1507-13.
Delmas PD, Licata AA, Reginster JY, et al. Fracture risk reduction during treatment with teriparatide is independent of pre-treatment bone turnover. Bone 2006; 39: 237-43.
Langdahl BL, Rajzbaum G, Jakob F, et al. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS) . Calcif Tissue Int 2009; 85: 484-93.
Walsh JB, Lems WF, Karras D, et al. Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS) . Calcif Tissue Int 2012; 90: 373-83.
Ljunggren O, Barrett A, Stoykov I, et al. Effective osteoporosis treatement with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis : The European Forsteo Observational Study. BMC Musculoskelet Disord 2013; 14: 251-63.
Jilka RL,Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 1999; 104: 371-3.
Greenspan SL, Bone HG, Ettinger MP, et al. Treatment of osteoporosis with parathyroid hormone study group. Ann Intern Med 2007; 146: 326-39.
Shrader SP, Raggucci KR. Parathyroid hormone (1-84) and treatment of osteoporosis. Ann Pharmacother 2005; 39: 1511-6.
Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: A review of the evidence and suggested guidelines for its use. Endocr Rev 2005; 26: 688-703.
Nakamura T, Sugimoto T, Nakano T, et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab 2012; 97: 3097-106.
Nakano T, Shiraki M, Sugimoto T, et al. Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: Subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial. J Bone Miner Metab 2014; 32: 441-6.
Fujita T, Fukunaga M, Itabashi A, et al. Once-weekly injection of low-dose teriparatide (28.2 mg) reduced the risk of vertebral fracture in patients with primary osteoporosis. Calcif Tissue Int 2014; 94: 170-5.
Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab 2010; 95: 151-8.
Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH (1-31) NH (2) ] in postmenopausal women with osteoporosis. Bone 2013; 53: 160-6.
Ettinger B, San Martin J, Crans G, et al. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 2004; 19: 745-50.
Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003; 349: 1207-15.
Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH (1-34) ] in postmenopausal osteoporosis. J Bone Miner Res 2011; 26: 503-11.
Walker MD, Cusano NE, Sliney Jr. J, et al. Combination therapy with risedronate and teriparatide in male osteoporosis. Endocrine 2013; 44: 237-46.
Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: Final results of the randomized, controlled European Study of Forsteo (EUROFORS) . J Bone Miner Res 2009; 24: 726-36.
Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone 2013; 52: 360-5.
Huang HT, Kang L, Huang PJ, et al. Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: A case report. Menopause 2012; 19: 1360-3.
Kwon YD, Lee DW, Choi BJ, et al. Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 2012; 23: 2721-5.
